|Bid||13.63 x 800|
|Ask||15.00 x 900|
|Day's Range||13.33 - 14.09|
|52 Week Range||5.00 - 15.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.00|
CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, will host an analyst and investor day on June 26, 2018 from 12:00pm to 2:00pm Eastern Time in New York City. Members of CymaBay’s senior management team will provide an update on the company's clinical development of seladelpar in patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). The meeting will also feature presentations by prominent liver experts Dr. Christopher Bowlus, UC Davis Health, Dr. Stephen Harrison, Pinnacle Clinical Research, and Dr. Gideon Hirschfield, University of Birmingham, UK, who will discuss their perspectives on current and novel approaches to treating PBC and NASH.
LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on CymaBay Therapeutics, Inc. (NASDAQ: CBAY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBAY as the Company's latest news hit the wire. On May 08, 2018, the Company announced the initiation of Phase-2b proof of concept clinical trials of seladelpar for the treatment of patients with non-alcoholic steatohepatitis (NASH). The Company started the Phase-2b study with the screening of patients for the clinical trials.
CymaBay Therapeutics, Inc. (CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the quarter ended March 31, 2018. “We’ve had an eventful start to the year with the achievement of significant clinical and operational milestones thus far in 2018,” said Sujal Shah, President and Chief Executive Officer of CymaBay. “Having strengthened our balance sheet with a successful financing early in the first quarter, our teams have been singularly focused on advancing seladelpar in both primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH).
CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it began screening of patients for a phase 2b proof of concept study of seladelpar for the treatment of non-alcoholic steatohepatitis (NASH). NASH, a disease linked to the metabolic syndrome which is associated with obesity and diabetes, is a growing global concern for which no treatment is currently approved. The disease is manifested by the accumulation of fat in the liver that leads to chronic liver inflammation and ultimately to fibrosis and cirrhosis.
NEWARK, Calif., May 01, 2018-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...
NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.
CymaBay Therapeutics’ (CBAY) MBX-2982 is under evaluation as a novel therapeutic agent. The company has yet to disclose its target indication. The drug was synthesized as a GPR119 agonist and is shown to increase glucose-dependent insulin secretion in animal models and in vitro. Non-clinical studies have shown MBX-2982 to have desirable effects on blood glucose levels.
CymaBay Therapeutics’ (CBAY) second product candidate, arhalofenate, is being developed for the treatment of gout. The drug has been studied in five phase two clinical trials in patients suffering from gout and has consistently demonstrated reduction of gout flares and serum uric acid (or sUA). Gout flares are recurring and painful episodes of joint inflammation.
CymaBay Therapeutics (CBAY) is currently developing seladelpar for treating primary biliary cholangitis (or PBC), which is an autoimmune disease that causes progressive destruction of the bile ducts in the liver. The company also plans to develop seladelpar for treating non-alcoholic steatohepatitis (or NASH). NASH is a serious chronic liver disease caused by excessive fat accumulation in the liver, which results in inflammation and cellular injury that can progress to fibrosis and cirrhosis and potentially liver failure.
CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.
Stock Monitor: Can-Fite BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on CymaBay Therapeutics, Inc. (NASDAQ: ...
NEW YORK, NY / ACCESSWIRE / April 12, 2018 / Biotech stocks Keryx and CymaBay were both flying higher in Wednesday trading on positive news. Keryx announced that it had received the 2018 Corporate Innovator ...
CymaBay launched to a month-high Wednesday after unveiling strong data for a liver disease treatment — to the detriment of Intercept which has struggled with its rival drug.
Seladelpar maintains potent anti-cholestatic and anti-inflammatory activity and appears safe and well tolerated, with no drug-induced pruritus, through 26 weeks of treatment Results from the extended study ...
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / CymaBay Therapeutics, Inc. (NASDAQ: CBAY ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018 at 4:30 PM Eastern ...
High growth companies such as Myomo and Cymabay Therapeutics has a positive future outlook in terms of their returns, profitability and cash flows. The prospects of these companies tend toRead More...